GSA Capital Partners LLP Acquires 43,086 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

GSA Capital Partners LLP boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 218.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,831 shares of the specialty pharmaceutical company's stock after purchasing an additional 43,086 shares during the period. GSA Capital Partners LLP owned about 0.11% of Supernus Pharmaceuticals worth $1,959,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 398 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at $43,000. Meeder Asset Management Inc. bought a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $47,000. Innealta Capital LLC purchased a new position in Supernus Pharmaceuticals in the 2nd quarter worth about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after acquiring an additional 352 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at $487,595.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Georges Gemayel sold 14,213 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company's stock, valued at approximately $487,595.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the sale, the chief executive officer now owns 926,172 shares of the company's stock, valued at $33,971,988.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SUPN shares. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Stock Down 0.2 %

Supernus Pharmaceuticals stock traded down $0.06 during midday trading on Wednesday, reaching $37.77. 382,252 shares of the stock traded hands, compared to its average volume of 451,424. The stock has a market cap of $2.09 billion, a P/E ratio of 35.39 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37. The stock's fifty day moving average is $33.23 and its 200-day moving average is $30.79.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. During the same period last year, the company posted ($0.29) EPS. The business's revenue was up 14.2% on a year-over-year basis. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.